Dr. Aditya Bardia is an Associate Professor in the Medicine Department at Harvard Medical School and Attending Physician at Massachusetts General Hospital Cancer Center, Boston, Massachusetts. He is the Director of Breast Cancer Research in Medical Oncology at Massachusetts General Hospital. He has led several high-impact clinical trials investigating novel therapies and translational studies in breast cancer including lead of the clinical development of the antibody drug conjugate, sacituzumab govitecan, now FDA-approved for triple-negative breast cancer. He is the author of more than 150 peer-reviewed papers. He is the recipient of Young Investigator Award from the ASCO Conquer Cancer Foundation and Career Catalyst Award for Susan G. Komen Foundation. Dr. Bardia is a faculty member of molecular tumor board by ASCO University and receipt of FASCO.

Dr. Claudine Isaacs is a Professor of Medicine and Oncology, Associate Director for Clinical Research and Leader of the Clinical Breast Cancer Program at the Lombardi Comprehensive Cancer Center (LCCC) at Georgetown University.  She is also the Medical Director of the Jess and Mildred Fisher Center for Hereditary Cancer and Clinical Genomics Research.  She has extensive experience in the conduct of clinical trials focusing on all aspects of breast cancer and currently serves as Co-Chair Endocrine Resistance Working Group of the Translational Breast Cancer Research Consortium (TBCRC) and as Co-Chair of the Clinical Trials Operations Working Group for the I-SPY 2 Trial. She has authored over 200 peer-reviewed publications and edited two textbooks. She has served on a number of national committees including the Scientific Program Committees at ASCO, the ASCO Breast Cancer Guideline Advisory Group, the Breast Oncology Local Diseases Task Force of the Breast Steering Committee of the NCI.